Table 2 Advances in CAR-T cell therapy for solid tumors from ESMO2024

QH104

Allogeneic B7H3 CAR-γδT

Phase I trial (NCT06018363)

Recurrent GBM

7 (2 females, 5 males, median age 60)

6.5 m

ORR 42.9%, DCR 100%

No DLT, grade ≥ 3 CRS, ICANS, or GvHD

[7]

BRG01

Autologous EBV Gp350 CAR-T

Phase I trial (NCT05864924)

Advanced metastatic NPC

11 (exhibiting 60-100% Gp350 expression)

N/A

Tumor shrinkage rates 75% (including CR); all PFSs > 6 m

No DLT, grade ≥ 2 CRS, ICANS, or treatment-related deaths

[8]

BNT211-01

Autologous CLDN6 CAR-T ± mRNA vaccine

Phase I trial (NCT04503278)

R/R CLDN6⁺ solid tumor

59 (median age 48, 56% male; median 4 prior treatment lines)

N/A

ORR 38%, DCR 69%

64% grade 3–4 treatment-related AEs, 39% serious related AEs

[9]

MT-302

in vivo TROP2 CAR-T (mRNA)

Phase I trial (NCT05969041)

Advanced epithelial tumor

N/A

N/A

N/A

N/A

[10]

EU307

Autologous IL-18-secreting GPC3 CAR-T

Phase I trial (NCT05783570)

GPC3⁺ advanced HCC

N/A

N/A

N/A

N/A

[11]

BTRP003L

Autologous hypoxia-regulated and dnTGFβRII-armored EGP-1 CAR-T

Preclinical study

Gastrointestinal tumor

N/A

N/A

Enhanced CAR-T expression and cytokine release in a hypoxic environment but lower activation levels under normoxic conditions

No observable AEs

[12]